<DOC>
	<DOC>NCT00061126</DOC>
	<brief_summary>A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body. Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.</brief_summary>
	<brief_title>ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male 18 years of age or older Has tumor tissue available for diagnostics Failed front line luteinizing hormonereleasing hormone analogue (LHRH) such as leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression. Patients must continue on a LHRH analogue (unless the patient had an orchiectomy) throughout the course of the study ECOG score of 0 or 1 Any prior chemotherapy for prostate cancer besides hormonal therapy (including no prior EGFr targeting agent) Prior history of cancer other than prostate carcinoma within the past 5 years that has required treatment or been active (prior basal cell carcinoma is allowed) Known to be HIV positive Myocardial infarction within one year prior to entering the study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>PSA</keyword>
	<keyword>Hormone refractory</keyword>
	<keyword>Rising PSA</keyword>
</DOC>